

# Ana Fernandez-Teijeiro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3525423/publications.pdf>

Version: 2024-02-01

31  
papers

822  
citations

623188

14  
h-index

525886

27  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1258  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Retinoblastoma Presentation and Analysis by National Income Level. <i>JAMA Oncology</i> , 2020, 6, 685.	3.4	192
2	qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1301-1308.	3.3	133
3	Combining Gene Expression Profiles and Clinical Parameters for Risk Stratification in Medulloblastomas. <i>Journal of Clinical Oncology</i> , 2004, 22, 994-998.	0.8	81
4	Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome–positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL–94, ALL–99 and ALL–2005. <i>British Journal of Haematology</i> , 2011, 154, 600-611.	1.2	50
5	Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin’s Lymphoma. <i>PLoS ONE</i> , 2016, 11, e0149072.	1.1	42
6	Familial retinoblastoma due to intronic LINE-1 insertion causes aberrant and noncanonical mRNA splicing of the RB1 gene. <i>Journal of Human Genetics</i> , 2016, 61, 463-466.	1.1	33
7	Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28557.	0.8	31
8	Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group. <i>HemaSphere</i> , 2020, 4, e329.	1.2	31
9	Incidence of Retinoblastoma Has Increased: Results from 40 European Countries. <i>Ophthalmology</i> , 2021, 128, 1369-1371.	2.5	26
10	The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. <i>The Lancet Global Health</i> , 2022, 10, e1128-e1140.	2.9	24
11	Secondary central nervous system metastases in children with neuroblastoma. , 1996, 27, 529-533.		22
12	L-Asparaginase and Steroids-associated Hypertriglyceridemia Successfully Treated With Plasmapheresis in a Child With Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, e122-e124.	0.3	21
13	Reversible Cardiomyopathy Secondary to $\pm$ -Interferon in an Infant. <i>Pediatric Cardiology</i> , 1999, 20, 293-294.	0.6	19
14	Travel burden and clinical presentation of retinoblastoma: analysis of 1024 patients from 43 African countries and 518 patients from 40 European countries. <i>British Journal of Ophthalmology</i> , 2021, 105, 1435-1443.	2.1	19
15	Near fatal cerebellar swelling in familial hemophagocytic lymphohistiocytosis. <i>Pediatric Neurology</i> , 2004, 30, 361-364.	1.0	17
16	Frequency of low-level and high-level mosaicism in sporadic retinoblastoma: genotype–phenotype relationships. <i>Journal of Human Genetics</i> , 2020, 65, 165-174.	1.1	16
17	Application of Microarrays to Neurological Disease. <i>Archives of Neurology</i> , 2003, 60, 676.	4.9	11
18	Longer follow-up confirms major improvement in outcome in children and adolescents with Philadelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and haematopoietic stem cell transplantation. Results from the Spanish Cooperative Study SHOP/ALL–2005. <i>British Journal of Haematology</i> , 2013, 162, 419-421.	1.2	9

#	ARTICLE	IF	CITATIONS
19	Clinical research tools in pediatric oncology: challenges and opportunities. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 149-160.	2.7	9
20	Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of care. <i>Journal of Neuro-Oncology</i> , 2018, 137, 205-213.	1.4	8
21	Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease. <i>Journal of Nuclear Medicine</i> , 2021, 62, 338-341.	2.8	7
22	Childhood and adolescent lymphoma in Spain: incidence and survival trends over 20 years. <i>Clinical and Translational Oncology</i> , 2018, 20, 1289-1301.	1.2	6
23	HB Puerta del Sol [HBA1:c.148A>C], HB Valdecilla [HBA2:c.3G>T], HB Gran Vía [HBA2:c.98T>G], HB Macarena [HBA2:c.358C>T] and HB El Retiro [HBA2:c.364_366dupGTC]: description of five new hemoglobinopathies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 553-60.	1.4	4
24	Assessment of Waldeyer's ring in pediatric and adolescent Hodgkin lymphoma patients: Importance of multimodality imaging: Results from the EuroNet-PC1 trial. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28903.	0.8	4
25	ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain. <i>Clinical and Translational Oncology</i> , 2019, 21, 1763-1770.	1.2	2
26	<sup>18</sup> F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1524-1530.	2.8	1
27	New wind for the Spanish Federation of Scientific Oncological Societies (FESEO). <i>Clinical and Translational Oncology</i> , 2018, 20, 805-807.	1.2	1
28	Tumor Ã³seo de cÃ³lulas gigantes en techo orbitario de paciente con retinoblastoma bilateral. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2019, 94, 200-203.	0.1	1
29	A prospective biological study in relation to a family with Li-Fraumeni syndrome. <i>Clinical and Translational Oncology</i> , 2012, 14, 396-398.	1.2	0
30	Retrospective study of feasibility of high-dose methotrexate in adult osteosarcoma patients over 40 years.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22509-e22509.	0.8	0
31	The novel p.Gly306Asp perforin mutation causes Familial Hemophagocytic Lymphohistiocytosis type 2 (FHL-2) probably due to a critical role of Gly306 in the pore-forming perforin domain.. <i>LymphoSign Journal</i> , 0, , .	0.1	0